This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2010 Oct;56(10):1015-7.

Ocular side effects of bisphosphonates: A case report and literature review

Meredith McKague¹, Derek Jorgenson, Kelly A Buxton

Affiliations

PMID: 20944044
PMCID: PMC2954081

Review

Ocular side effects of bisphosphonates: A case report and literature review

Meredith McKague et al. Can Fam Physician. 2010 Oct.

. 2010 Oct;56(10):1015-7.

Authors

Meredith McKague¹, Derek Jorgenson, Kelly A Buxton

Affiliation

¹ University of Saskatchewan, Department of Academic Family Medicine, West Winds Primary Health Centre, Saskatoon, SK S7M 3Y5. m.mckague@usask.ca

PMID: 20944044
PMCID: PMC2954081

No abstract available

PubMed Disclaimer

Similar articles

[Osteoporosis and bisphosphonates].
Zuber MA. Zuber MA. Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8. Z Rheumatol. 2007. PMID: 17955251 German. No abstract available.
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276. Curr Med Res Opin. 2006. PMID: 16709313 Review.
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD, Möller G. Ringe JD, et al. Rheumatol Int. 2009 Dec;30(2):213-21. doi: 10.1007/s00296-009-0940-5. Rheumatol Int. 2009. PMID: 19430791
[Treating with what? Therapy for how long?].
[No authors listed] [No authors listed] MMW Fortschr Med. 2005 Dec 15;147(51-52):62-3. MMW Fortschr Med. 2005. PMID: 16402713 German. No abstract available.
The use of bisphosphonates in women: when to use and when to stop.
Gatti D, Adami S, Viapiana O, Rossini M. Gatti D, et al. Expert Opin Pharmacother. 2015;16(16):2409-21. doi: 10.1517/14656566.2015.1087506. Epub 2015 Sep 11. Expert Opin Pharmacother. 2015. PMID: 26357942 Review.

See all similar articles

Cited by

Novel combined pharmacological strategy to alleviate acute phase response following zoledronic acid treatment.
Chen CH, Yeap EK, Hsu CH, Lu YM, Cheng TL, Lee TC, Ho CJ, Li JY, Shen HY, Huang HT, Lu CC, Lin SY. Chen CH, et al. Arch Osteoporos. 2024 Oct 15;19(1):97. doi: 10.1007/s11657-024-01452-w. Arch Osteoporos. 2024. PMID: 39404970 Free PMC article.
Ocular toxicity from systemically administered xenobiotics.
Gokulgandhi MR, Vadlapudi AD, Mitra AK. Gokulgandhi MR, et al. Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1277-91. doi: 10.1517/17425255.2012.708337. Epub 2012 Jul 18. Expert Opin Drug Metab Toxicol. 2012. PMID: 22803583 Free PMC article. Review.
Acute unilateral anterior uveitis following zoledronic acid infusion: A case report.
Anandasayanan K, Malaravan M, Suganthan N. Anandasayanan K, et al. SAGE Open Med Case Rep. 2020 Jul 20;8:2050313X20944305. doi: 10.1177/2050313X20944305. eCollection 2020. SAGE Open Med Case Rep. 2020. PMID: 32742658 Free PMC article.
Risedronate-associated scleritis: a case report and review of the literature.
Hemmati I, Wade J, Kelsall J. Hemmati I, et al. Clin Rheumatol. 2012 Sep;31(9):1403-5. doi: 10.1007/s10067-012-2035-z. Epub 2012 Aug 5. Clin Rheumatol. 2012. PMID: 22864810 Review.
Ocular Side Effects of Systemic Drugs Used in Dermatology.
Prakash B, Kumar HM, Palaniswami S, Lakshman BH. Prakash B, et al. Indian J Dermatol. 2019 Nov-Dec;64(6):423-430. doi: 10.4103/ijd.IJD_353_18. Indian J Dermatol. 2019. PMID: 31896837 Free PMC article.

See all "Cited by" articles

References

1. Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, et al. Canadian consensus conference on osteoporosis, 2006 update. J Obstet Gynaecol Can. 2006;28(2 Suppl 1):S95–112. - PMC - PubMed
1. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570–8. - PubMed
1. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23(4):508–16. - PubMed
1. Khan A. Bisphosphonate-associated osteonecrosis of the jaw. Can Fam Physician. 2008;54:1019–21. - PMC - PubMed
1. Moore MM, Beith JM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust. 2008;188(6):370–1. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information